利拉鲁肽或西格列汀对超重2型糖尿病患者的胰腺影响:一项12周随机安慰剂对照试验
该12周随机双盲平行组试验纳入55例接受二甲双胍和/或磺脲类治疗的2型糖尿病患者,比较利拉鲁肽1.8 mg、西格列汀100 mg与安慰剂对胰腺外分泌功能和形态的影响。无患者发生胰腺炎;西格列汀使十二指肠内胰液分泌量增加16.3 mL(95%CI -0.3至32.9;P=0.05),利拉鲁肽未改变外分泌功能;两药仅引起血浆胰酶浓度短暂轻度升高,胰腺形态未见改变。
要点
- 无患者发生胰腺炎;西格列汀使十二指肠内胰液分泌量增加16.3 mL(95%CI -0.3至32.9;P=0.05),利拉鲁肽未改变外分泌功能。
- 两药治疗12周均未升高脂肪酶/淀粉酶水平,但利拉鲁肽在第6周升高脂肪酶23.5 U/L(95%CI 2.1-44.8;P=0.03),西格列汀在第2和6周升高淀粉酶13.7 U/L(95%CI 3.4-23.9;P=0.03)。
- 两药治疗12周均升高血浆胰蛋白酶原(利拉鲁肽34.6 µg/mL,95%CI 15.1-54.2,P=0.001;西格列汀23.9 µg/mL,95%CI 4.9-42.9,P=0.01),胰腺形态未见改变。
核心结论
- 12周利拉鲁肽或西格列汀治疗仅导致2型糖尿病患者血浆胰酶浓度短暂轻度升高;除西格列汀引起轻微十二指肠内胰液分泌量增加外,胰腺外分泌功能未受影响。
- 这些细微变化的长期临床后果需进一步研究。
研究设计与样本
- 随机双盲平行组试验,纳入55例接受二甲双胍和/或磺脲类药物治疗的2型糖尿病患者。
- 参与者每日一次接受利拉鲁肽1.8 mg(n=19)、西格列汀100 mg(n=19)或匹配安慰剂(n=17),共12周。
- 主要终点为外分泌功能变化(十二指肠内胰液分泌量、脂肪酶活性、粪便弹性蛋白酶-1和糜蛋白酶);次要终点包括血浆酶浓度和胰腺形态(经MRI评估)变化。
主要发现
- 无患者发生胰腺炎。
- 西格列汀使十二指肠内胰液分泌量增加16.3 mL(95%CI -0.3至32.9;P=0.05),利拉鲁肽未改变胰腺外分泌功能。
- 两药治疗12周均未升高脂肪酶/淀粉酶水平;但利拉鲁肽在第6周升高脂肪酶23.5 U/L(95%CI 2.1-44.8;P=0.03),西格列汀在第2和6周升高淀粉酶13.7 U/L(95%CI 3.4-23.9;P=0.03)。
- 两药治疗12周均升高血浆胰蛋白酶原(利拉鲁肽:34.6 µg/mL,95%CI 15.1-54.2,P=0.001;西格列汀:23.9 µg/mL,95%CI 4.9-42.9,P=0.01)。
- 两药均未改变胰腺形态,但利拉鲁肽有增加胰腺体积的趋势(7.7 cm3,95%CI -1.2至16.6;P=0.09);治疗引起的体积增大与淀粉酶水平升高相关。
临床怎么用
- 原文未据此给出推荐。
局限性
- 这些细微变化的长期临床后果需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the mechanistic effects of the glucagon-like peptide 1 (GLP-1) receptor agonist liraglutide and the dipeptidyl peptidase 4 (DPP-4) inhibitor sitagliptin on (exocrine) pancreatic physiology and morphology. RESEARCH DESIGN AND METHODS: For this randomized, double-blind, parallel-group trial, 55 patients with type 2 diabetes treated with metformin and/or sulfonylurea agents were included. Participants received liraglutide 1.8 mg (n = 19), sitagliptin 100 mg (n = 19), or matching placebos (n = 17) once daily for 12 weeks. The primary end point was change in exocrine function (intraduodenal pancreatic fluid secretion, lipase activity, fecal elastase-1, and chymotrypsin). Secondary end points included changes in plasma enzyme concentrations and pancreatic morphology (per MRI). RESULTS: No patient developed pancreatitis. Sitagliptin increased intraduodenal pancreatic fluid secretion by 16.3 mL (95% CI -0.3 to 32.9; P = 0.05), whereas liraglutide did not change exocrine pancreatic function. Neither therapy increased lipase/amylase levels after 12 weeks. However, liraglutide increased lipase levels after 6 weeks (23.5 U/L [95% CI 2.1-44.8]; P = 0.03) and sitagliptin increased amylase levels after 2 and 6 weeks (13.7 U/L [95% CI 3.4-23.9]; P = 0.03). Both drugs increased plasma trypsinogen after 12 weeks (liraglutide: 34.6 µg/mL [95% CI 15.1-54.2], P = 0.001; sitagliptin: 23.9 µg/mL [95% CI 4.9-42.9], P = 0.01). Neither changed pancreatic morphology, although liraglutide tended to increase pancreatic volume (7.7 cm3 [95% CI -1.2 to 16.6]; P = 0.09). Treatment-induced volume expansion was associated with increased amylase levels. CONCLUSIONS: A 12-week treatment with liraglutide or sitagliptin only resulted in a brief and modest increase of plasma pancreatic enzyme concentrations in patients with type 2 diabetes. Apart from a minimal sitagliptin-induced increase in intraduodenal fluid secretion, pancreatic exocrine function was unaffected. The long-term clinical consequences of these discrete changes require further study.
引用
- Smits MM, Tonneijck L, Muskiet MH, et al. Pancreatic Effects of Liraglutide or Sitagliptin in Overweight Patients With Type 2 Diabetes: A 12-Week Randomized, Placebo-Controlled Trial. Diabetes Care. 2016. PMID: 27998910. doi:10.2337/dc16-0836
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。